Literature DB >> 31418100

Epidemiology of invasive meningococcal disease in Greece, 2006-2016.

Anastasia Flountzi1,2, Theano Georgakopoulou3, Sooria Balasegaram4, Konstantinos Kesanopoulos5, Athanasia Xirogianni5, Anastasia Papandreou5, Georgina Tzanakaki6.   

Abstract

The present study describes the epidemiology of invasive meningococcal disease (IMD) in Greece for the period 2006-2016. Combined data from notified and laboratory-confirmed IMD cases were obtained from the two involved National Centres (Epidemiology and Reference Laboratory). Laboratory identification and typing was carried out by both conventional (culture) and molecular methods (PCR, MLST, PorA, and FetA typing). A total of 796 IMD cases were notified; of those, 720 (91%) were laboratory confirmed. Overall, a decline on the annual incidence of confirmed cases was observed, ranging from 0.91 (2006) to 0.47 (2016) /100,000. A similar trend was observed in most age groups especially in children 0-4 years (7.7 to 2.9/100,000), with the exception of an increase in the incidence rate in adults > 20 years (0.21 to 0.32/100,000). The overall case fatality rate was 6.5% (52/796), annual range 2-13%. Among 658 strains which were typed by sero/genogroup, 80% were identified as MenB (annual range 65-92%); however, a decline was observed in MenB incidence from 5.3 (2006) to 2.7 (2016), among infants and toddlers, while MenW (1%), MenY (2%), and MenA (1%) remained low. During the 11 years, the annual incidence of IMD declined by 50%, especially in the 0-4-year age group, due mainly to MenB. Continuous surveillance of IMD is important for the development of future vaccination and public health policies.

Entities:  

Keywords:  Antimicrobial susceptibility; Clonal complex; Epidemiology; Invasive meningococcal disease (IMD); fetA; porA

Mesh:

Substances:

Year:  2019        PMID: 31418100     DOI: 10.1007/s10096-019-03668-y

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  29 in total

Review 1.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

2.  Simultaneous single-tube PCR assay for the detection of Neisseria meningitidis, Haemophilus influenzae type b and Streptococcus pneumoniae.

Authors:  G Tzanakaki; M Tsopanomichalou; K Kesanopoulos; R Matzourani; M Sioumala; A Tabaki; J Kremastinou
Journal:  Clin Microbiol Infect       Date:  2005-05       Impact factor: 8.067

3.  Phenotypic assessment of Neisseria meningitidis isolates obtained from patients with invasive meningococcal disease in Greece, 1993-2003: implications for serogroup B vaccines based on PorA serosubtype antigens.

Authors:  Georgina Tzankaki; Fani Markou; Konstantinos Kesanopoulos; Stamatina Levidiotou; Anastasia Pangalis; Mariza Tsolia; Vassiliki Liakou; Eleni Papapavasiliou; Aliki Voyiatzi; Athina Kansouzidou; Maria Foustoukou; Caroline Blackwell; Jenny Kremastinou
Journal:  Vaccine       Date:  2005-08-08       Impact factor: 3.641

4.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

5.  Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013.

Authors:  Michael Bröker; Stéphane Emonet; Cecilia Fazio; Susanne Jacobsson; Maria Koliou; Markku Kuusi; David Pace; Metka Paragi; Alexander Pysik; Maria João Simões; Anna Skoczynska; Paola Stefanelli; Maija Toropainen; Muhamed-Kheir Taha; Georgina Tzanakaki
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  A cross-sectional vaccination coverage study in preschool children attending nurseries-kindergartens: Implications on economic crisis effect.

Authors:  Theano Georgakopoulou; Damianos Menegas; Antonis Katsioulis; Maria Theodoridou; Jenny Kremastinou; Christos Hadjichristodoulou
Journal:  Hum Vaccin Immunother       Date:  2017-01-02       Impact factor: 3.452

Review 7.  The Global Evolution of Meningococcal Epidemiology Following the Introduction of Meningococcal Vaccines.

Authors:  Stephen I Pelton
Journal:  J Adolesc Health       Date:  2016-08       Impact factor: 5.012

8.  Molecular characterization of a collection of Neisseria meningitidis isolates from Croatia, June 2009 to January 2014.

Authors:  Suzana Bukovski; Paola Vacca; Anna Anselmo; Ivica Knezovic; Cecilia Fazio; Arianna Neri; Andrea Ciammaruconi; Antonella Fortunato; Anna Maria Palozzi; Silvia Fillo; Florigio Lista; Paola Stefanelli
Journal:  J Med Microbiol       Date:  2016-07-22       Impact factor: 2.472

9.  Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.

Authors:  Markus Knuf; Olivier Romain; Klaus Kindler; Uta Walther; Phu-My Tran; Heidemarie Pankow-Culot; Thomas Fischbach; Dorothee Kieninger-Baum; Véronique Bianco; Yaela Baine; Jacqueline Miller
Journal:  Eur J Pediatr       Date:  2013-01-11       Impact factor: 3.183

10.  Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine.

Authors:  Georgina Tzanakaki; Eva Hong; Konstatinos Kesanopoulos; Athanasia Xirogianni; Stefania Bambini; Luca Orlandi; Maurizio Comanducci; Alessandro Muzzi; Muhamed-Kheir Taha
Journal:  BMC Microbiol       Date:  2014-04-29       Impact factor: 3.605

View more
  1 in total

Review 1.  Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.

Authors:  Federico Martinón-Torres; Muhamed-Kheir Taha; Markus Knuf; Victoria Abbing-Karahagopian; Michele Pellegrini; Rafik Bekkat-Berkani; Véronique Abitbol
Journal:  Pathog Glob Health       Date:  2021-09-27       Impact factor: 2.894

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.